The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
Open accessAbstract
BACKGROUND: Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited. METHODS: In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority. RESULTS: A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drug-coated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority). CONCLUSIONS: Among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes. (Funded by Medtronic; ONYX ONE ClinicalTrials.gov number, NCT03344653.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationValgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citationThird Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Thygesen, K., Alpert, J. S., White, H. D., Jaffe, A. S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.001 · Cited by 2,621
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
Self-citation2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · EuroIntervention · doi:10.4244/eijy19m01_01 · Cited by 1,259
Self-citationWatanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 857
Urban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040167 · Cited by 823
Self-citationPolymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Urban, P., Meredith, I. T., Abizaid, A., Pocock, S. J., Carrié, D., Naber, C., Lipiecki, J., Richardt, G., Iñiguez, A., Brunel, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503943 · Cited by 818
Self-citation
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Self-citationHalvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., Ozaki, Y., Morice, M.-C., Chevalier, B., Onuma, Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108749 · Cited by 593
Self-citationThompson, A., Fleischmann, K. E., Smilowitz, N. R., de las Fuentes, L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001285 · Cited by 365
Metadata
- Authors
- Windecker, S., Latib, A., Kedhi, E., Kirtane, A. J., Kandzari, D. E., Mehran, R., Price, M. J., Abizaid, A., Simon, D. I., Worthley, S. G., Zaman, A., Hudec, M., Poliacikova, P., Abdul Ghapar, A. K. B., Selvaraj, K., Petrov, I., Mylotte, D., Pinar, E., Moreno, R., Fabbiocchi, F., Pasupati, S., Kim, H.-S., Aminian, A., Tie, C., Wlodarczak, A., Hur, S.-H., Marx, S. O., Jankovic, I., Brar, S., Bousquette, L., Liu, M., & Stone, G. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-26
- Volume
- 382
- Issue
- 13
- Pages
- 1208-1218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3005734342
- Cited by
- 291
- References
- 19
- FWCI
- 42.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. https://app.cochat.ai/papers/10.1056/nejmoa1910021
- The paper
- Windecker, S., Latib, A., Kedhi, E., Kirtane, A. J., Kandzari, D. E., Mehran, R., Price, M. J., Abizaid, A., Simon, D. I., Worthley, S. G., Zaman, A., Hudec, M., Poliacikova, P., Abdul Ghapar, A. K. B., Selvaraj, K., Petrov, I., Mylotte, D., Pinar, E., Moreno, R., . . . Stone, G. W. (2020). Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1910021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.